Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics; D002986:Clinical Trials as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D051794:Von Hippel-Lindau Tumor Suppressor Protein; C497446:VHL protein, human